The purpose of the study was to determine the effect of vitamin
V ITAMIN D deficiency is common in elderly people because of lesser exposure to sunlight, decreased efficiency of the skin in producing vitamin D, and deficient nutrition (1, 2) . It may be an important risk factor for hip fractures, which are a major cause of morbidity and mortality in the elderly. One yr after a fracture, mobility is restored in less than half of the patients, and about 20% of the patients will have died (3). Although true osteomalacia is rare, a suboptimal vitamin D status impairs the production of 1,25dihydroxyvitamin D (1,25-(OH),D), which is essential for active intestinal calcium absorption. The ensuing secondary hyperparathyroidism will result in increased bone turnover and predominantly cortical bone loss, thus increasing the risk of fractures (4). Patients with a hip fracture often have lower vitamin D levels than do controls of similar age (5,6). Moreover, positive correlations of vitamin D levels with bone mineral density (BMD) of the proximal femur and vertebrae have been found in elderly groups and among younger women with a poor vitamin D status (7, 8) .
Vitamin D supplementation of 400 IU daily in elderly people has little or no side effects and improves vitamin D status. In elderly people who are 25-hydroxyvitamin D (250HD)-deficient, supplementation increases serum 1,25-(OH),D levels and intestinal calcium absorption and de-creases the secretion of PTH (9,101. This suggests that vitamin D supplementation may reduce bone turnover and bone loss and consequently may lower fracture incidence. However, experimental data from randomized, double-blind trials are scarce. observed that vitamin D supplementation reduced wintertime bone loss from the spine in a group of postmenopausal women, whereas in another study (12), no effect of a vitamin D supplement on appendicular bone loss was found in men. There is also some evidence that an annual injection of vitamin D protects against fractures (13). In a recent study (141, a daily supplement of 800 IU vitamin D, and 1200 mg calcium reduced bone loss and the incidence of hip fractures in elderly women, but to what extent vitamin D caused this effect cannot be determined.
Inasmuch as vitamin D supplementation may offer a safe and substantial contribution to the prevention of osteoporosis and hip fractures in the elderly, we studied the effect of a daily supplement of 400 IU vitamin D, during a 2-yr period on bone turnover and bone loss from the hip and distal radius, in a double-blind, placebo-controlled trial in women ages 70 yr and older.
Materials and Methods

Study population
Elderly people ages 70 yr and older were asked to participate in a clinical trial on the effect of vitamin D supplementation on the incidence of hip fractures (15). Exclusion criteria were hip fracture in the past, total hip prosthesis, and recent history of urolithiasis, hypercalcemia, or sarcoidosis. Female residents of homes for the elderly and apartments for the elderly were asked to participate in an additional study involving BMD and biochemical measurements.
The women had to be reasonably mobile in order to be able to visit the hospital for BMD measurements, which were performed at baseline (to), after 1 yr (t,), and after 2 yr (t2 
Results
A total of 348 women were randomized to vitamin D (n = 177) or placebo treatment (n = 171). The baseline characteristics are presented in Table 1 . There were no substantial differences in these characteristics between the groups. One woman who appeared to have hypercalcemia at baseline was excluded from further participation. One participant in the vitamin D group reported a rash that disappeared after discontinuing the trial medication. At the second and third visit, 6 and 5 women in the placebo group and 7 and 2 women in the vitamin D group, respectively, seemed to be taking a supplement containing vitamin D, and these were excluded from the analysis. In 283 and 248 women, respectively, the measurements were repeated at t, and t2. The reasons for not having a follow-up measurement are presented in Table 2 . The drop-out rate was 19% in the first yr, 11% in the second yr, and 29% for the whole study period. The drop-out rate was somewhat greater in the placebo group, mainly because of a higher death rate (P = 0.12 in the first yr, P = 0.08 for the total period), although none of the differences were significant.
Compliance
The compliance in the women who had repeated measurements was good. According to the yearly questionnaire, 85% used one tablet daily, and 14% used between three and six tablets weekly at t, as well as at t2. The analysis of the remaining tablets showed a slightly better compliance in the second study yr. In the first yr, 63% had used between six and seven tablets weekly, and 4% had used less than three weekly; in the second yr, these compliance rates were 78% and l%, respectively. Of the women receiving the vitamin D supplement, only 5 participants (3%) did not achieve a serum 250HD level higher than 30 nmol/L at t,, whereas 68.4% of the participants in the placebo group had serum levels below 30 nmol/L. JCE & M . 1995 Vol80. 
Biochemical results
The biochemical measurements at t, and t, are presented in Table 3 . Vitamin D supplementation significantly increased serum 250HD ( +35 nmol/L) and 1,25-(OH),D ( + 7.0 pmol/L) levels at t,. The median serum PTH(l-84) value decreased in the vitamin D group, whereas there was a slight increase in the placebo group, the effect at t, (-0.74 pmol/L)) being statistically significant. Serum calcitonin increased in the group treated with vitamin D, but there was a similar increase in the placebo group. Although serum osteocalcin, alkaline phosphatase, bone alkaline phosphatase, and urinary hydroxyproline/creatinine demonstrated a slight relative decrease at t,, this effect of vitamin D supplementation was not significant. A significant relative increase was observed for the urinary calcium/creatinine ratio (+0.5%).
Bone mineral measurements
Bone loss at t, and t, was expressed as the difference in mean change in BMD (%), as presented in Table 4 and Fig.   1 . To enhance precision, weight loss was used as a covariate for all measurement sites, and serum SHBG at baseline was used for the trochanter and distal radius, as these were significantly related to bone loss at these measurement sites.
Adding the covariates to the model did not markedly alter the results. The effect of vitamin D supplementation at t, was an increase in BMD of 1.9% for the left and 2.6% for the right femoral neck. During the whole period (ti and t2), a statistically significant gain was observed at the left and right femoral neck (P = 0.01 and P = 0.002, respectively, analysis of variance for repeated measurements), and no significant effects were observed for the other measurement sites. In multiple regression analysis, the effects seemed to be most prominent in the first study yr (to to tl), in which the differences in change between the groups were 1.5% and 1.8% for the left and right femoral neck, respectively. In the second study yr (ti to t2), minor positive effects were observed as well, but these were not significant. No significant effects were found at the left and right trochanter and the distal radius.
Modification
Baseline serum 250HD, serum SHBG, and calcium intake were tested as potential modifiers of the effect of vitamin D on bone loss during the first yr. The effect of vitamin D supplementation seemed to be independent of baseline serum 250HD as well as of serum 250HD corrected for season (all P > 0.20). A greater effect in favor of the vitamin D group was found at higher serum SHBG levels at all measurement sites. This modification was significant at the left femoral neck (P = 0.01) and right femoral neck (P = 0.05), and of borderline significance at the left trochanter (P = O.OB), but not at the other measurement sites. At the left trochanter, a greater effect of vitamin D supplementation was found at lower calcium intakes (P = 0.004). In contrast, the effect of vitamin D supplementation was greater at higher calcium intakes at the right femoral neck (P = 0.03). 
Discussion
We found that supplementation with 400 IU vitamin Ds daily in elderly women improved the vitamin D status to that of the young adult range (23), slightly increased serum 1,25-(OH),D levels, slightly decreased PTH secretion, and increased BMD at the femoral neck. No effect on the parameters of bone turnover was observed, except for a small increase in the urinary calcium/creatinine ratio. Higher serum levels of 1,25-(OH&D may increase calcitonin secretion in elderly women (241, but this was not confirmed by our results.
The increase in BMD at the femoral neck was most apparent in the first yr (between 1.5 and 1.8%), whereas during the second yr there was still some additional gain (0.2 and l.l%), although it was not statistically significant. Indeed, some of the effects of vitamin D supplementation can be expected to be confined to the first yr (4, 25). Vitamin D supplementation may increase calcium availability, which may promote the mineralization of previously undermineralized bone and the rate at which new bone is mineralized (26). The lower serum PTH levels will reduce bone turnover, thus decreasing the remodeling space and the quantity of new bone with lower mineral content (25). However, this could not be confirmed by a decrease in the markers of bone turnover. Although all were lower in the vitamin D group, JCE & M . 1995 Vol80 none of the observed effects were statistically significant. 1,25-(OH),D is known to stimulate osteocalcin and alkaline phosphatase production in the osteoblasts, which may counteract the effect of lowering turnover (26). When the balance between bone resorption and formation is negative, a decrease in bone turnover will lower the rate of age-related bone loss (27). This effect will persist for as long as vitamin D supplementation is continued. The small, nonsignificant benefit during the second yr suggests a decrease of the agerelated bone loss, but a longer follow-up period would have been necessary to confirm this more subtle effect. Dawson-Hughes et al. (11) observed a reduction of wintertime bone loss from the lumbar spine as a result of vitamin D supplementation in younger women, and no effect on whole-body BMD. Eighty percent of the skeleton is cortical bone. Therefore, they suggested that trabecular bone is more sensitive to vitamin D deficiency than cortical bone is. Heikinheimo et al. (13) found that vitamin D supplementation greatly reduced the incidence of upper limb fractures, whereas a much smaller and nonsignificant reduction in the incidence of lower limb fractures was observed. This suggests that the effect of vitamin D supplementation depends on the skeletal region rather than on the ratio of cortical to trabecular bone. In our study, the increase in BMD was confined to the femoral neck, an area with a relatively high content of cortical bone, and no effect of vitamin D supplementation was found at the femoral trochanter and distal radius, which are predominantly trabecular areas. We did not measure BMD at the lumbar spine, as this measurement has been found to be inaccurate because of the high prevalence of spinal osteoarthritis in elderly people (27) . In a population of elderly women, Chapuy et al. (14) observed a greater effect of a combination of 800 IU vitamin D and 1200 mg calcium daily on BMD of the proximal femur and serum PTH than was found in our study. It is unlikely that the higher dose of vitamin D is responsible for the difference in the results. The additional increase in serum 250HD when using a 800-IU dose is negligible (9), which is confirmed by the similar increase of serum 250HD in both studies. Although mean baseline serum 250HD and age were similar, the dietary calcium intake was much lower in the Chapuy study, which may account for the higher baseline serum PTH levels and the subsequently greater reduction after supplementation. This suggests that the calcium supplement contributed substantially to the observed effects in this study.
We expected participants with serum 250HD concentrations below 30 nmol/L to benefit more from vitamin D supplementation than participants with higher levels. In a cross-sectional analysis of the baseline data in this group (22), we found a clear distinction between vitamin Ddeficient and vitamin D-replete participants at a serum 250HD of approximately 30 nmol/L. Higher serum PTH and osteocalcin and lower BMD values were observed only in participants with values below this threshold. Surprisingly, the effect of vitamin D supplementation was not significantly greater in participants with low baseline serum 250HD levels than in those with higher levels. When the serum 250HD levels were corrected for the season of measurement, the results were similar. Only about 30% of the participants had baseline serum 250HD levels higher than 30 nmol/L, and this group may be too small to detect modification of the effect of vitamin D supplementation. At the left and right femoral neck and left trochanter, the effect of vitamin D supplementation was greater in participants with high serum SHBG than in those with lower serum levels. Inasmuch as serum SHBG has been found to be the main determinant of the levels of free estrogen in elderly women, it can be used as an inverse marker of remaining estrogen activity (28-30). High serum SHBG, i.e. low estrogen activity, may be associated with lower calcium absorption because of decreased sensitivity of the gut to 1,25-(OH),D or to a direct effect of estrogen on the gut (31, 32). Indeed, higher serum PTH levels were observed at baseline among participants in whom low serum 250HD was combined with high serum SHBG (22). In this group, higher serum 1,25-(OH),D levels will be required to maintain adequate absorption, which will be possible only when the serum 250HD levels are sufficient. The active metabolite 1,25-(OH),D is essential for active intestinal calcium absorption. When calcium intake is high, the contribution of passive calcium diffusion to intestinal calcium absorption may be higher. The effect of vitamin D supplementation may be less in these subjects. This could only be confirmed at the left trochanter with high statistical significance, whereas (surprisingly) the opposite was found at the right femoral neck.
It may be expected that an increase in BMD at the femoral neck will reduce the risk of hip fracture. However, quantification of this reduction is difficult and may be different for femoral neck and trochanteric fractures. Using data from Cummings et al. (33) on the relation between BMD and fracture risk, the effect of vitamin D supplementation on BMD in this study would correspond with a reduction in the incidence of femoral neck fractures by 12-17%. The risk of trochanteric fractures may be unchanged or even decreased inasmuch as BMD of the femoral neck is a predictor of trochanteric fractures as well.
As could be expected in an elderly population, the dropout rate was substantial. The total number of deaths was almost twice as high in the placebo group, which may bias the results. However, a higher number of frail elderly, who are more prone to bone loss, may have remained in the vitamin D supplemented group, so the true effect of vitamin D supplementation may be even greater rather than smaller.
We conclude that vitamin D supplementation with 400 IU daily slightly increases serum 1,25-(OH),D and lowers PTH secretion without side effects. Bone loss is prevented at the femoral neck but not at the femoral trochanter and distal radius. The effect is independent of the baseline vitamin D status, but our data suggest that elderly women with little remaining estrogen activity benefit more than women with greater remaining estrogen activity. Therefore vitamin D supplementation may be a safe method for the prevention of hip fractures in the elderly. 
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